CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02730871
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:16.945747+00:00
Published At: 2019-05-17T00:00:00+00:00
Record Updated At: 2019-05-29
Results Posted At: 2019-05-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Open-angle Glaucoma", "Ocular Hypertension"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-05-29"
protocolSection.identificationModule.nctId: "NCT02730871"
protocolSection.identificationModule.officialTitle: "Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA\u00ae) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV\u00ae)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-05-17"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.